

**Table S1.** All the identified components from *Sparassis crispa* extracts and their UPLC-MS data.

Peak No.	Retention time (min)	Positive ESI mode			Negative ESI mode			Exact mass	Formula	Identification	Confidence level <sup>a</sup>
		Adduct ion m/z	Mass error (ppm)	Fragment ion m/z	Adduct ion m/z	Mass error (ppm)	Fragment ion m/z				
1	0.71	175.1190 [M+H] <sup>+</sup>	0.558	158, 130, 116	173.1043 [M-H] <sup>-</sup>	-0.687	-	174.1117	C <sub>6</sub> H <sub>14</sub> O <sub>2</sub> N <sub>4</sub>	arginine	III
2	0.76	183.0864 [M+H] <sup>+</sup> 205.0683 [M+Na] <sup>+</sup>	0.521 0.198	165, 147, 129, 111	181.0716 [M-H] <sup>-</sup>	-0.836	-	182.0790	C <sub>6</sub> H <sub>14</sub> O <sub>6</sub>	mannitol (6) <sup>b</sup>	I
3	0.80	-	-	-	191.0195 [M-H] <sup>-</sup>	-0.920	173, 129, 111, 85	192.0270	C <sub>6</sub> H <sub>8</sub> O <sub>7</sub>	citric acid (2)	I
4	1.05	276.1554 [M+H] <sup>+</sup>	0.010	159, 144, 131, 120, 116, 88	274.1406 [M-H] <sup>-</sup>	-0.927	-	275.1481	C <sub>11</sub> H <sub>21</sub> O <sub>5</sub> N <sub>3</sub>	ethyl-L-glutaminyll-L-threonine	III
5	1.07	-	-	-	147.0297 [M-H] <sup>-</sup>	-1.337	129, 115, 103	148.0372	C <sub>5</sub> H <sub>8</sub> O <sub>5</sub>	ribono-1,4-lactone	III
6	1.31	207.0499 [M+H] <sup>+</sup>	0.052	-	205.0352 [M-H] <sup>-</sup>	-1.004	173, 155, 143, 111	206.0427	C <sub>7</sub> H <sub>10</sub> O <sub>7</sub>	citric acid monomethyl ester	III
7	1.49	-	-	-	147.0661 [M-H] <sup>-</sup>	-1.238	129, 101	148.0736	C <sub>6</sub> H <sub>12</sub> O <sub>4</sub>	mevalonic acid	III
8	1.69	-	-	-	131.0348 [M-H] <sup>-</sup>	-0.109	113	132.0423	C <sub>5</sub> H <sub>8</sub> O <sub>4</sub>	methylsuccinic acid	III
9	2.44	-	-	-	145.0505 [M-H] <sup>-</sup>	0.911	127, 101	146.0579	C <sub>6</sub> H <sub>10</sub> O <sub>4</sub>	3-methylglutaric acid	III
10	2.61	185.0809 [M+H] <sup>+</sup> 207.0629 [M+Na] <sup>+</sup>	0.457 0.338	141, 109	-	-	-	184.0736	C <sub>9</sub> H <sub>12</sub> O <sub>4</sub>	crispacolide	III
11	2.64	-	-	-	211.0247 [M-H] <sup>-</sup>	-0.717	193, 165	212.0321	C <sub>9</sub> H <sub>8</sub> O <sub>6</sub>	sparalide B	III
12	2.65	298.0967 [M+H] <sup>+</sup>	-0.425	280, 262, 136	296.0820 [M-H] <sup>-</sup>	-1.058	-	297.0896	C <sub>11</sub> H <sub>15</sub> O <sub>3</sub> N <sub>5</sub> S	5'-deoxy-5'-methylthioadenosine	III
13	2.74	229.1548 [M+H] <sup>+</sup>	-0.572	-	227.1400 [M-H] <sup>-</sup>	-0.510	183, 168, 152, 139, 124, 114	228.1474	C <sub>11</sub> H <sub>20</sub> O <sub>3</sub> N <sub>2</sub>	leucylproline	III
14	2.90	-	-	-	211.0247 [M-H] <sup>-</sup>	-0.290	193, 165	212.0321	C <sub>9</sub> H <sub>8</sub> O <sub>6</sub>	hanabiratakeliide C	III
15	3.00	-	-	-	195.0298 [M-H] <sup>-</sup>	-0.649	165	196.0372	C <sub>9</sub> H <sub>8</sub> O <sub>5</sub>	hanabiratakeliide B	III

Peak No.	Retention time (min)	Positive ESI mode			Negative ESI mode			Exact mass	Formula	Identification	Confidence level <sup>a</sup>
		Adduct ion m/z	Mass error (ppm)	Fragment ion m/z	Adduct ion m/z	Mass error (ppm)	Fragment ion m/z				
16	3.30	-	-	-	188.0927 [M-H] <sup>-</sup>	-0.698	144, 116	189.1001	C <sub>8</sub> H <sub>15</sub> O <sub>4</sub> N	2-aminooctanedioic acid	III
17	3.33	-	-	-	195.0298 [M-H] <sup>-</sup> 391.0669 [2M-H] <sup>-</sup>	-0.547 -0.358	177, 149	196.0372	C <sub>9</sub> H <sub>8</sub> O <sub>5</sub>	sparalide C	III
18	3.48	183.0652 [M+H] <sup>+</sup>	0.244	-	181.0506 [M-H] <sup>-</sup>	-0.453	123, 95, 67	182.0579	C <sub>9</sub> H <sub>10</sub> O <sub>4</sub>	methyl-2, 4-dihydroxy-6-methylbenzoate	III
19	3.54	-	-	-	195.0298 [M-H] <sup>-</sup>	-0.495	177, 149	196.0372	C <sub>9</sub> H <sub>8</sub> O <sub>5</sub>	hanabiratakeli A	III
20	3.70	181.0497 [M+H] <sup>+</sup>	0.634	-	179.0349 [M-H] <sup>-</sup>	-0.235	149	180.0423	C <sub>9</sub> H <sub>8</sub> O <sub>4</sub>	5-hydroxy-7-methoxyphthalide	III
21	3.84	-	-	-	311.0773 [M-H] <sup>-</sup>	0.191	293, 275, 245, 179, 149, 97	312.0854	C <sub>14</sub> H <sub>16</sub> O <sub>8</sub>	sparalide A	III
22	3.97	377.1459 [M+H] <sup>+</sup>	0.820	359, 341, 243, 99	375.1310 [M-H] <sup>-</sup>	0.006	-	376.1383	C <sub>17</sub> H <sub>20</sub> O <sub>6</sub> N <sub>4</sub>	riboflavin (1)	I
23	4.08	211.0602 [M+H] <sup>+</sup> 233.0421 [M+Na] <sup>+</sup>	0.616 0.281	193, 165	209.0456 [M-H] <sup>-</sup>	0.303	191, 163	210.0528	C <sub>10</sub> H <sub>10</sub> O <sub>5</sub>	6-hydroxy-5,7-dimethoxyphthalide	III
24	4.18	211.0601 [M+H] <sup>+</sup> 233.0421 [M+Na] <sup>+</sup>	0.001 0.109	193, 165	209.0455 [M-H] <sup>-</sup>	0.016	191, 163	210.0528	C <sub>10</sub> H <sub>10</sub> O <sub>5</sub>	4-hydroxy-5,7-dimethoxy-1-isobenzofuranone	III
25	4.57	251.1278 [M+H] <sup>+</sup> 273.1095 [M+Na] <sup>+</sup>	0.257 -0.953	233, 215, 205, 197, 187, 169, 159, 145	-	-	-	250.1200	C <sub>14</sub> H <sub>18</sub> O <sub>4</sub>	ainsliatone A (3)	I
26	4.67	-	-	-	173.0817 [M-H] <sup>-</sup>	1.341	129, 111	174.0892	C <sub>8</sub> H <sub>14</sub> O <sub>4</sub>	suberic acid	III
27	4.75	345.1181 [M+H] <sup>+</sup>	0.352	-	343.1033 [M-H] <sup>-</sup>	-0.453	285, 257, 195, 167, 137, 109	344.1107	C <sub>15</sub> H <sub>20</sub> O <sub>9</sub>	sparoside A	III

Peak No.	Retention time (min)	Positive ESI mode			Negative ESI mode			Exact mass	Formula	Identification	Confidence level <sup>a</sup>
		Adduct ion m/z	Mass error (ppm)	Fragment ion m/z	Adduct ion m/z	Mass error (ppm)	Fragment ion m/z				
28	5.18	213.0756 [M+H] <sup>+</sup>	-0.657	185, 157, 155, 127, 99	211.0611 [M-H] <sup>-</sup>	-0.553	-	212.0685	C <sub>10</sub> H <sub>12</sub> O <sub>5</sub>	methyl 2,4-dihydroxy-3-methoxy-6-methylbenzoate	III
29	5.35	181.0495 [M+H] <sup>+</sup>	-0.471	151	179.0348 [M-H] <sup>-</sup>	-0.570	149	180.0423	C <sub>9</sub> H <sub>8</sub> O <sub>4</sub>	5-methoxy-7-hydroxyphthalide	III
30	5.41	213.0757 [M+H] <sup>+</sup>	-0.328	155, 127	211.0612 [M-H] <sup>-</sup>	0.158	-	212.0685	C <sub>10</sub> H <sub>12</sub> O <sub>5</sub>	methyl dihydroxymethoxy-methylbenzoate	III
31	5.69	195.0652 [M+H] <sup>+</sup>	0.075	165, 135	-	-	-	194.0579	C <sub>10</sub> H <sub>10</sub> O <sub>4</sub>	meconin	III
32	5.70	195.0651 [M+H] <sup>+</sup>	-0.232	165, 135	-	-	-	194.0579	C <sub>10</sub> H <sub>10</sub> O <sub>4</sub>	5,7-dimethoxyphthalide	III
33	6.35	197.0809 [M+H] <sup>+</sup>	0.125	169, 139, 111	-	-	-	196.0736	C <sub>10</sub> H <sub>12</sub> O <sub>4</sub>	sparassol	III
34	6.42	-	-	-	181.0717 [M-H] <sup>-</sup>	-0.394	163, 149, 131, 119, 101, 89, 71, 59	182.0790	C <sub>6</sub> H <sub>14</sub> O <sub>6</sub>	glucitol	III
35	6.72	-	-	-	181.0716 [M-H] <sup>-</sup>	-	163, 131, 119, 101	182.0790	C <sub>6</sub> H <sub>14</sub> O <sub>6</sub>	dulcitol	III
36	6.83	218.2115 [M+H] <sup>+</sup>	0.157	200, 174, 156, 130, 106	-	-	-	217.2042	C <sub>12</sub> H <sub>27</sub> O <sub>2</sub> N	2-amino-1,3-dodecanediol	III
37	6.85	655.3084 [M+H] <sup>+</sup>	-0.295	343, 315, 244, 226, 112	653.2943 [M-H] <sup>-</sup>	0.398	-	654.3013	C <sub>32</sub> H <sub>42</sub> O <sub>9</sub> N <sub>6</sub>	stellarin C	III
38	6.97	-	-	-	201.1131 [M-H] <sup>-</sup>	-0.658	183, 139	202.1205	C <sub>10</sub> H <sub>18</sub> O <sub>4</sub>	3-tert-butyladipic acid	III
39	7.15	262.2377 [M+H] <sup>+</sup>	0.113	244, 226, 136, 118, 100	-	-	-	261.2304	C <sub>14</sub> H <sub>31</sub> O <sub>3</sub> N	2-amino-1,3,4-tetradecanetriol	III

Peak No.	Retention time (min)	Positive ESI mode			Negative ESI mode			Exact mass	Formula	Identification	Confidence level <sup>a</sup>
		Adduct ion m/z	Mass error (ppm)	Fragment ion m/z	Adduct ion m/z	Mass error (ppm)	Fragment ion m/z				
40	7.25	376.2483 [M+H] <sup>+</sup>	0.146	360, 332, 316, 288	374.2336 [M-H] <sup>-</sup>	-0.112	-	375.2410	C <sub>22</sub> H <sub>33</sub> O <sub>4</sub> N	tuberostemonine	III
41	7.60	436.2693 [M+H] <sup>+</sup>	-0.170	-	434.2552 [M-H] <sup>-</sup>	0.803	416, 398, 206, 193	435.2621	C <sub>24</sub> H <sub>37</sub> O <sub>6</sub> N	salternamide D	III
42	7.69	393.2068 [M+H] <sup>+</sup>	1.994	365, 337, 309	-	-	-	392.1988	C <sub>25</sub> H <sub>28</sub> O <sub>4</sub>	xanthoangelol	III
43	7.87	293.2110 [M+H] <sup>+</sup>	-0.516	275, 233, 177, 151, 99, 71	-	-	-	292.2083	C <sub>18</sub> H <sub>28</sub> O <sub>3</sub>	9-hydroxy-10,14-octadecadien-12-ynoic acid	III
44	8.09	459.3104 [M+H] <sup>+</sup>	-0.307	441, 423, 277, 259, 241	-	-	-	458.3032	C <sub>28</sub> H <sub>42</sub> O <sub>5</sub>	strophasterol C	III
45	8.20	556.3052 [M+H] <sup>+</sup>	-1.024	496, 434, 394, 374, 324	554.2906 [M-H] <sup>-</sup>	0.884	-	555.2985	C <sub>35</sub> H <sub>41</sub> O <sub>5</sub> N	3-(acetyloxy)-17-(benzoyloxy)-7-[O-(phenylmethyl)oxime] androst-5-en-7-one	III
46	8.33	267.1590 [M+H] <sup>+</sup>	-0.433	-	265.1444 [M-H] <sup>-</sup>	-0.575	247	266.1518	C <sub>15</sub> H <sub>22</sub> O <sub>4</sub>	clitocybulol C	III
47	8.45	295.2266 [M+H] <sup>+</sup>	-0.411	277, 221	293.2120 [M-H] <sup>-</sup>	-0.710	275	294.2195	C <sub>18</sub> H <sub>30</sub> O <sub>3</sub>	3β-hydroxy-11,12-O-isopropylidenedrimene	III
48	8.48	-	-	-	329.2331 [M-H] <sup>-</sup>	-0.751	229, 211, 171, 139	330.2406	C <sub>18</sub> H <sub>34</sub> O <sub>5</sub>	9,12,13-trihydroxy-15-octadecenoic acid	III
49	8.61	277.2161 [M+H] <sup>+</sup>	-0.529	-	275.2016 [M-H] <sup>-</sup>	-0.194	231	276.2089	C <sub>18</sub> H <sub>28</sub> O <sub>2</sub>	morocetic acid	III
50	8.77	332.1847 [M+H] <sup>+</sup>	-2.754	274, 264, 206	-	-	-	331.1784	C <sub>19</sub> H <sub>25</sub> O <sub>4</sub> N	antrodin D	III
51	8.79	339.1597 [M+H] <sup>+</sup>	1.811	311, 283, 251	-	-	-	358.1518	C <sub>21</sub> H <sub>22</sub> O <sub>4</sub>	4-hydroxyderricin	III

Peak No.	Retention time (min)	Positive ESI mode			Negative ESI mode			Exact mass	Formula	Identification	Confidence level <sup>a</sup>
		Adduct ion m/z	Mass error (ppm)	Fragment ion m/z	Adduct ion m/z	Mass error (ppm)	Fragment ion m/z				
52	8.99	526.3309 [M+H] <sup>+</sup>	-1.217	-	524.3160 [M-H] <sup>-</sup>	1.706	508, 506, 492, 490, 474, 360, 257	525.3243	C <sub>35</sub> H <sub>43</sub> O <sub>3</sub> N	1-(18-benzamido-3β-hydroxy-5α-androstan-17β-yl)-3-phenyl-2-propen-1-one	III
53	9.11	181.1223 [M+H] <sup>+</sup>	-0.035	153, 149, 121	-	-	-	180.1150	C <sub>11</sub> H <sub>16</sub> O <sub>2</sub>	butylated hydroxyanisole	III
54	9.31	353.2298 [M+H] <sup>+</sup>	0.665	337, 335, 321, 303	351.2155 [M-H] <sup>-</sup>	1.446	-	352.2223	C <sub>16</sub> H <sub>28</sub> O <sub>3</sub> N <sub>6</sub>	3-cyclohexene-1-butylaldehyde-3-hydroxy-α-isopropyl-1-methyl-2-oxo-disemicarbazone	III
55	9.69	313.2374 [M+H] <sup>+</sup>	0.204	-	311.2227 [M-H] <sup>-</sup>	-0.394	293, 249, 171	312.2301	C <sub>18</sub> H <sub>32</sub> O <sub>4</sub>	5,8-dihydroxy-9,12-octadecadienoic acid	III
56	9.86	-	-	-	267.1599 [M-H] <sup>-</sup>	-1.057	249, 223	268.1675	C <sub>15</sub> H <sub>24</sub> O <sub>4</sub>	ustusol B	III
57	10.34	-	-	-	265.1447 [M-H] <sup>-</sup>	0.632	244	266.1518	C <sub>15</sub> H <sub>22</sub> O <sub>4</sub>	3-hydroxy-(4,2-hydroxy-6-methyl)-2 heptyl benzoic acid	III
58	10.56	311.2216 [M+H] <sup>+</sup>	-0.405	293, 275, 257, 223	309.2070 [M-H] <sup>-</sup>	-0.429	291, 273, 209, 185, 99	310.2144	C <sub>18</sub> H <sub>30</sub> O <sub>4</sub>	porrigenic acid	III

Peak No.	Retention time (min)	Positive ESI mode			Negative ESI mode			Exact mass	Formula	Identification	Confidence level <sup>a</sup>
		Adduct ion m/z	Mass error (ppm)	Fragment ion m/z	Adduct ion m/z	Mass error (ppm)	Fragment ion m/z				
59	10.63	330.1707 [M+H] <sup>+</sup>	2.015	272, 262, 204	-	-	-	329.1627	C <sub>19</sub> H <sub>23</sub> O <sub>4</sub> N	antrodin C	III
60	10.70	293.2109 [M+H] <sup>+</sup>	-0.755	275, 229, 177, 161, 151, 133	-	-	-	292.2038	C <sub>18</sub> H <sub>28</sub> O <sub>3</sub>	12-oxo-phytodienoic acid	III
61	11.34	233.1171 [M+H] <sup>+</sup>	-0.390	215, 197, 187, 169, 159, 95	-	-	-	232.1094	C <sub>14</sub> H <sub>16</sub> O <sub>3</sub>	fraxinellone (5)	I
62	11.36	-	-	-	415.2112 [M-H] <sup>-</sup>	-0.735	119	414.2042	C <sub>24</sub> H <sub>30</sub> O <sub>6</sub>	armillarin	III
63	12.12	337.2736 [M+H] <sup>+</sup>	-0.479	293, 275	-	-	-	336.2664	C <sub>21</sub> H <sub>36</sub> O <sub>3</sub>	3-methyl-5-pentyl-2-furanundecanoic acid	III
64	12.51	-	-	-	649.3440 [M-H] <sup>-</sup>	1.551	562, 341, 323, 279, 87	650.3514	C <sub>31</sub> H <sub>54</sub> O <sub>14</sub>	nicandrose E	III
65	12.78	315.2530 [M+H] <sup>+</sup>	-0.083	-	313.2383 [M-H] <sup>-</sup>	-0.296	295, 277, 201, 183	314.2457	C <sub>18</sub> H <sub>34</sub> O <sub>4</sub>	1,3-di(isobutoxycarbonyl)-2,4,4-trimethylpentane	III
66	12.92	318.3002 [M+H] <sup>+</sup>	-0.316	300, 282, 264, 68	-	-	-	317.2930	C <sub>18</sub> H <sub>39</sub> O <sub>3</sub> N	2-amino-1,3,4-trihydroxyoctadecane	III
67	13.13	-	-	-	295.2275 [M-H] <sup>-</sup>	-1.111	277, 251, 228, 183	296.2351	C <sub>18</sub> H <sub>32</sub> O <sub>3</sub>	10-hydroxy-8,12-octadecadienoic acid	III
68	13.31	279.2317 [M+H] <sup>+</sup>	-0.561	235	-	-	-	278.2246	C <sub>18</sub> H <sub>30</sub> O <sub>2</sub>	α-eleostearic acid	III
69	13.49	-	-	-	295.2276 [M-H] <sup>-</sup>	-0.908	277, 251, 228, 183	296.2351	C <sub>18</sub> H <sub>32</sub> O <sub>3</sub>	8-oxo-9-octadecenoic acid	III

Peak No.	Retention time (min)	Positive ESI mode			Negative ESI mode			Exact mass	Formula	Identification	Confidence level <sup>a</sup>
		Adduct ion m/z	Mass error (ppm)	Fragment ion m/z	Adduct ion m/z	Mass error (ppm)	Fragment ion m/z				
70	14.05	-	-	-	489.3066 [M-H] <sup>-</sup>	-0.667	279	490.3142	C <sub>25</sub> H <sub>46</sub> O <sub>9</sub>	3-hydroxy-2-[[[(9Z)-1-oxo-9-hexadecen-1-yl]oxy]propyl β-D-galactopyranoside	III
71	14.20	-	-	-	297.2433 [M-H] <sup>-</sup>	-0.869	279, 251, 207, 155	298.2508	C <sub>18</sub> H <sub>34</sub> O <sub>3</sub>	6,7-epoxystearic acid	III
72	14.33	445.3159 [M+H] <sup>+</sup>	-0.068	409, 343, 285, 267, 187	443.3013 [M-H] <sup>-</sup>	-0.354	-	444.3087	C <sub>24</sub> H <sub>44</sub> O <sub>7</sub>	1-(9-octadecenoate)-β-D-glucopyranose	III
73	14.36	295.2267 [M+H] <sup>+</sup>	-0.241	255, 129, 101	-	-	-	294.2195	C <sub>18</sub> H <sub>30</sub> O <sub>3</sub>	9-oxo-octadecadienoic acid	III
74	14.50	-	-	-	503.3012 [M-H] <sup>-</sup>	-0.371	383, 361, 339, 299, 279	504.3087	C <sub>29</sub> H <sub>44</sub> O <sub>7</sub>	2,3-seco-2,3-dicarboxyplatanic acid	III
75	15.09	782.5689 [M+H] <sup>+</sup>	-0.346	727, 573, 555, 499, 363, 345, 335, 327, 317, 307, 299, 289, 271	-	-	-	782.5697	C <sub>48</sub> H <sub>78</sub> O <sub>8</sub>	2,3-bis(4-hydroxy-3-methoxybenzyl)butane-1,4-diyl ditetradecanoate	III
76	15.46	427.3205 [M+H] <sup>+</sup>	-0.332	409, 301, 283, 261, 243	425.3063 [M-H] <sup>-</sup>	0.222	-	426.3134	C <sub>28</sub> H <sub>42</sub> O <sub>3</sub>	9,11-dehydroergosterolp	III

Peak No.	Retention time (min)	Positive ESI mode			Negative ESI mode			Exact mass	Formula	Identification	Confidence level <sup>a</sup>
		Adduct ion m/z	Mass error (ppm)	Fragment ion m/z	Adduct ion m/z	Mass error (ppm)	Fragment ion m/z				
77	15.47	274.2739 [M+H] <sup>+</sup>	-0.714	256, 237, 84	-	-	-	273.2668	C <sub>16</sub> H <sub>35</sub> O <sub>2</sub> N	eroxide 2-amino-1,3-hexadecanediol	III
78	15.59	483.2868 [M+H] <sup>+</sup>	0.671	465, 422, 406	-	-	-	482.2781	C <sub>28</sub> H <sub>38</sub> O <sub>5</sub> N <sub>2</sub>	stachybotrin G	III
79	15.68	409.3100 [M+H] <sup>+</sup>	-0.261	391, 283, 265, 243, 225	-	-	-	408.3028	C <sub>28</sub> H <sub>40</sub> O <sub>2</sub>	ganoderaside D	III
80	15.69	391.2994 [M+H] <sup>+</sup>	-0.262	265, 225	-	-	-	390.2923	C <sub>28</sub> H <sub>38</sub> O	ergosta-1,5,7,9(11),22-pentaen-3-one	III
81	15.83	591.3885 [M+H] <sup>+</sup> 613.3708 [M+Na] <sup>+</sup>	-1.006 -0.391	411, 465, 425, 285, 245	-	-	-	590.3819	C <sub>34</sub> H <sub>54</sub> O <sub>8</sub>	3-O-β-D-glucopyranosyl ergosterol peroxide	III
82	16.14	340.2846 [M+H] <sup>+</sup>	-0.207	298, 280, 238, 112	-	-	-	339.2773	C <sub>20</sub> H <sub>37</sub> O <sub>3</sub> N	2-methyl-6-(11-oxododecyl)piperidin-3-yl acetate	III
83	16.50	307.2631 [M+H] <sup>+</sup>	-0.218	263	-	-	-	306.2559	C <sub>20</sub> H <sub>34</sub> O <sub>2</sub>	diroleuton	III
84	16.51	307.2631 [M+H] <sup>+</sup>	-0.185	292, 261, 219, 191, 173, 149, 123, 109	-	-	-	306.2559	C <sub>20</sub> H <sub>34</sub> O <sub>2</sub>	linolenic acid ethyl ester	III
85	16.63	429.3362 [M+H] <sup>+</sup>	-0.260	411, 393, 375, 303, 285, 267, 263, 249, 245, 227, 209	-	-	-	428.3290	C <sub>28</sub> H <sub>44</sub> O <sub>3</sub>	(5α,6α)-epoxy-ergosta-8(14),22-diene-3β,7β-diol	III



Peak No.	Retention time (min)	Positive ESI mode			Negative ESI mode			Exact mass	Formula	Identification	Confidence level <sup>a</sup>
		Adduct ion m/z	Mass error (ppm)	Fragment ion m/z	Adduct ion m/z	Mass error (ppm)	Fragment ion m/z				
86	16.64	368.3160 [M+H] <sup>+</sup>	0.243	326, 308, 266, 112	366.3012 [M-H] <sup>-</sup>	-0.348	-	367.3086	C <sub>22</sub> H <sub>41</sub> O <sub>3</sub> N	2-methyl-6-(13-oxotetradecyl)piperidin-3-yl acetate	III
87	16.67	326.3053 [M+H] <sup>+</sup>	-0.171	309, 121	-	-	-	325.2981	C <sub>20</sub> H <sub>39</sub> O <sub>2</sub> N	oleoylethanolamide	III
88	16.85	380.3159 [M+H] <sup>+</sup>	-0.159	350, 322, 267, 239	378.3013 [M-H] <sup>-</sup>	-0.178	-	379.3086	C <sub>23</sub> H <sub>41</sub> O <sub>3</sub> N	hurghamide D	III
89	16.90	445.3315 [M+H] <sup>+</sup>	0.480	427, 409, 391, 319, 301, 283, 279, 261, 265, 243, 225	-	-	-	444.3240	C <sub>28</sub> H <sub>44</sub> O <sub>4</sub>	3β,5α,9α-trihydroxyergosta-7,22-dien-6-one	III
90	16.99	393.3150 [M+H] <sup>+</sup>	-0.489	267, 227	-	-	-	392.3079	C <sub>28</sub> H <sub>40</sub> O	ergone	III
91	17.02	318.3002 [M+H] <sup>+</sup>	-0.222	300, 282, 100	-	-	-	317.2930	C <sub>18</sub> H <sub>39</sub> O <sub>3</sub> N	2-amino-1,3,4-octadecanetriol	III
92	17.03	-	-	-	339.2327 [M-H] <sup>-</sup>	-0.747	163	340.2402	C <sub>23</sub> H <sub>32</sub> O <sub>2</sub>	2,2'-methylenebis(4-methyl-6-tert-butylphenol)	III
93	17.56	-	-	-	279.2326 [M-H] <sup>-</sup>	-1.266	261	280.2402	C <sub>18</sub> H <sub>32</sub> O <sub>2</sub>	linoleic acid	III
94	17.92	282.2790 [M+H] <sup>+</sup>	0.501	265, 247, 191, 177, 163, 135, 121, 111	280.2650 [M-H] <sup>-</sup>	0.462	-	281.2719	C <sub>18</sub> H <sub>35</sub> NO	oleamide	III
95	18.05	411.3255 [M+H] <sup>+</sup>	-0.698	393, 285, 253, 245, 213,	409.3112 [M-H] <sup>-</sup>	0.016	-	410.3185	C <sub>28</sub> H <sub>42</sub> O <sub>2</sub>	3-hydroxyergosta-5,8,22-trien-7-one	III
96	18.24	429.3363 [M+H] <sup>+</sup> 451.3179 [M+Na] <sup>+</sup>	0.019 -0.745	411, 393, 375, 303, 287, 285,	-	-	-	428.3290	C <sub>28</sub> H <sub>44</sub> O <sub>3</sub>	ergosterol peroxide	III

Peak No.	Retention time (min)	Positive ESI mode			Negative ESI mode			Exact mass	Formula	Identification	Confidence level <sup>a</sup>
		Adduct ion m/z	Mass error (ppm)	Fragment ion m/z	Adduct ion m/z	Mass error (ppm)	Fragment ion m/z				
				269, 263, 249, 245, 209							
97	18.37	256.2635 [M+H] <sup>+</sup>	0.043	241, 213	-	-	-	255.2562	C <sub>16</sub> H <sub>33</sub> ON	hexadecanamide	III
98	18.48	397.3463 [M+H] <sup>+</sup>	-0.610	379, 271, 253, 231, 213	369.3393 [M+H] <sup>-</sup>	-0.474	-	396.3392	C <sub>28</sub> H <sub>44</sub> O	ergosterol (4)	I
99	18.58	384.3259 [M+H] <sup>+</sup>	-0.420	366, 261, 257	382.3114 [M-H] <sup>-</sup>	-0.523	-	383.3188	C <sub>26</sub> H <sub>41</sub> ON	veracintine	III
100	19.04	409.3099 [M+H] <sup>+</sup>	-0.555	283, 243	407.2952 [M-H] <sup>-</sup>	-0.354	-	408.3028	C <sub>28</sub> H <sub>40</sub> O <sub>2</sub>	ergosta-5,8,22-triene-3,11-dione	III
101	19.52	312.3259 [M+H] <sup>+</sup>	-0.517	265	-	-	-	311.3188	C <sub>20</sub> H <sub>41</sub> ON	2-nonadecanone-O-methyloxime	III
102	19.67	386.3416 [M+H] <sup>+</sup>	-0.496	370, 274, 258	-	-	-	385.3345	C <sub>26</sub> H <sub>43</sub> ON	4-azacholest-5-en-3-one	III
103	19.69	360.3260 [M+H] <sup>+</sup>	-0.282	344, 213, 134	358.3116 [M-H] <sup>-</sup>	0.279	-	359.3188	C <sub>24</sub> H <sub>41</sub> ON	N-(2-phenylethyl)hexadecanamide	III
104	20.47	284.2946 [M+H] <sup>+</sup>	-0.673	268, 241	-	-	-	283.2875	C <sub>18</sub> H <sub>37</sub> ON	stearamide	III
105	21.45	710.5559 [M+H] <sup>+</sup>	-0.893	532, 484, 338, 294, 276	-	-	-	709.5493	C <sub>41</sub> H <sub>75</sub> O <sub>8</sub> N	thraustochytroside A	III
106	21.54	-	-	-	772.5578 [M-H] <sup>-</sup>	-0.305	564, 546, 420, 292	773.5653	C <sub>42</sub> H <sub>79</sub> O <sub>11</sub> N	rhizoleucinoside	III
107	21.92	338.3417 [M+H] <sup>+</sup>	-1.182	321, 303, 247, 163, 149, 135, 111	-	-	-	337.3345	C <sub>22</sub> H <sub>43</sub> ON	erucamide	III
108	21.96	579.4978 [M+H] <sup>+</sup>	-0.866	-	577.4836 [M-H] <sup>-</sup>	-0.292	377, 313, 295, 281	578.4910	C <sub>36</sub> H <sub>66</sub> O <sub>5</sub>	1-(hydroxymethyl)-2[(1-oxohexadecyl)oxy]	III

Peak No.	Retention time (min)	Positive ESI mode			Negative ESI mode			Exact mass	Formula	Identification	Confidence level <sup>a</sup>
		Adduct ion m/z	Mass error (ppm)	Fragment ion m/z	Adduct ion m/z	Mass error (ppm)	Fragment ion m/z				
109	24.22	241.2161 [M+H] <sup>+</sup>	-0.401	-	239.2017 [M-H] <sup>-</sup>	0.111	221, 203	240.2089	C <sub>15</sub> H <sub>28</sub> O <sub>2</sub>	ethyl-ester-9,12-heptadecadienoic acid	III
110	24.84	241.2160 [M+H] <sup>+</sup>	-0.650	-	239.2017 [M-H] <sup>-</sup>	0.111	221, 203	240.2089 3.633	C <sub>15</sub> H <sub>28</sub> O <sub>2</sub>	3-(10-hydroxy-10-methylethyl)-5,8a-dimethyldecahydroazulen-4-ol (5β, 6α)-6,11-dihydroxyeudesmane	III

<sup>a</sup>) The confidence level of identity of all the identified components were determined following the four levels defined by the Metabolomics Standards Initiative. Level I : confidently identified compounds; Level II : Putatively annotated compounds; Level III: putatively annotated compound classes; Level IV: unknown compounds.

<sup>b</sup>) The bracketed bold figures showed the serial number of reference compounds.

**Table S2.** The virtual screening results for self-built 3D chemical database including 110 compounds in *S. crista* with four kinds of SFKs (Hck, Lyn, Fyn and Syk) as the receptors.

**(a) Hck**

#	Compound name	Total score <sup>a</sup>	Crash	Polar	Similarity	D score	PMF score	G score	Chem score	C score
01	10-hydroxy-8,12-octadecadienoic acid	11.08	-0.92	4.70	0.46	-144.69	-16.55	-248.00	-25.14	4
02	salternamide D	10.94	-3.49	4.73	0.57	-187.83	-22.93	-365.29	-29.51	4
03	hurghamide D	10.30	-3.05	1.44	0.43	-164.76	4.96	-286.54	-24.63	4
04	2-amino-1,3-hexadecanediol	10.09	-2.01	4.46	0.38	-89.72	-16.98	-201.38	-26.19	5
05	2-methyl-6-(13-oxotetradecyl)piperidin-3-yl acetate	9.64	-1.68	0.90	0.47	-179.22	6.61	-355.41	-28.75	4
06	oleoyl ethanolamide	9.52	-2.05	1.89	0.37	-147.84	6.84	-257.37	-26.11	4
07	9-hydroxy-10,14-octadecadien-12-ynoic acid	9.13	-2.61	2.25	0.37	-152.93	-1.75	-243.76	-23.85	5
08	2,2'-methylenebis(4-methyl-6-tert butylphenol)	6.97	-1.73	0.93	0.27	8.91	-21.25	-272.47	-27.14	5
09	3-cyclohexene-1-butyraldehyde-3-hydroxy- $\alpha$ -isopropyl-1-methyl-2-oxo-disemicarbazone	6.84	-1.29	4.93	0.50	-236.90	-19.59	-428.79	-39.95	4
10	antrodin D	6.32	-3.63	0.40	0.55	-83.14	-18.19	-158.84	-4.05	4
11	5 $\alpha$ ,6 $\alpha$ -epoxy-(22E,24R)-ergosta-8(14),22-diene-3 $\beta$ ,7 $\beta$ -diol	6.27	-3.72	1.41	0.43	-147.91	-19.09	-319.39	-29.15	4
-	RK20449 <sup>b</sup>	10.24	-1.14	2.11	0.71	-166.45	-81.46	-326.43	-34.69	5

**(b) Lyn**

#	Compound name	Total score <sup>a</sup>	Crash	Polar	Similarity	D score	PMF score	G score	Chem score	C score
01	thraustochytrioside A	11.60	-5.30	2.07	0.44	-121.35	-16.73	-219.41	-21.40	4
02	2,3-bis(4-hydroxy-3-methoxybenzyl)butane-1,4-diyl ditetradecanoate	10.33	-3.57	1.06	0.41	-214.55	3.26	-372.06	-31.81	5
03	9-hydroxy-10,14-octadecadien-12-ynoic acid	9.72	-1.38	4.15	0.49	-139.90	3.70	-241.73	-23.60	4
04	1-(9-octadecenoate)- $\beta$ -D-glucopyranose	9.43	-2.09	2.83	0.33	-154.63	-24.90	-308.10	-18.42	4
05	hurghamide D	9.30	-2.31	2.43	0.39	-133.97	-16.45	-234.93	-22.61	4
06	linolenic acid ethyl ester	9.25	-1.92	1.30	0.43	-60.32	-8.09	-150.06	-15.60	4
07	linoleic acid	8.41	-1.42	2.33	0.50	27.62	-20.11	-122.50	-17.89	5

#	Compound name	Total score <sup>a</sup>	Crash	Polar	Similarity	D score	PMF score	G score	Chem score	C score
08	salternamide D	8.24	-3.23	3.20	0.50	-161.63	-8.95	-272.14	-25.91	4
09	2-amino-1,3-hexadecanediol	8.22	-1.46	3.61	0.36	-94.74	-2.21	-220.80	-22.10	4
10	10-hydroxy-8,12-octadecadienoic acid	8.13	-1.30	3.27	0.58	-118.04	-5.55	-194.34	-19.87	5
11	2-amino-1,3,4-tetradecanetriol	7.90	-3.52	3.53	0.36	-132.73	-23.56	-223.69	-24.70	4
12	antrodin C	7.88	-1.92	2.01	0.30	-141.58	-4.70	-221.72	-23.68	4
13	sparoside A	7.68	-1.46	4.33	0.38	-130.97	-35.04	-202.86	-18.07	4
14	xanthoangelol	7.62	-3.37	1.97	0.49	-120.57	-7.98	-244.68	-27.34	4
15	antrodin D	7.59	-1.92	2.22	0.55	-74.60	-26.50	-139.27	-5.14	5
16	2-methyl-6-(13-oxotetradecyl)piperidin-3-yl acetate	7.55	-1.37	2.35	0.37	-151.12	-20.66	-281.24	-31.35	5
17	oleoyl ethanolamide	7.32	-1.39	2.75	0.34	-122.63	-27.37	-248.86	-26.24	4
18	9,11-dehydroergosterolperoxide	7.23	-1.52	1.16	0.36	-123.84	-8.61	-242.93	-26.40	4
19	5 $\alpha$ ,6 $\alpha$ -epoxy-(22E,24R)-ergosta-8(14),22-diene-3 $\beta$ ,7 $\beta$ -diol	6.68	-1.68	1.41	0.42	-126.19	-19.66	-265.73	-26.21	4
20	stachybotrin G	6.44	-3.23	2.06	0.50	-148.19	-22.74	-278.49	-26.62	4
21	ergosta-5,8,22-triene-3,11-dione	6.39	-2.29	0.35	0.39	-117.45	14.99	-254.63	-27.96	5
-	INNO-406 <sup>b</sup>	8.52	-1.59	1.63	0.51	-150.29	-51.63	-252.22	-34.28	5

(c) Fyn

#	Compound name	Total score <sup>a</sup>	Crash	Polar	Similarity	D score	PMF score	G score	Chem score	C score
01	thraustochytrioside A	11.28	-2.63	3.94	0.41	-140.27	-12.99	-259.44	-27.95	4
02	10-hydroxy-8,12-octadecadienoic acid	9.62	-0.95	3.27	0.55	-142.00	-12.25	-229.15	-23.84	5
03	antrodin D	8.61	-1.29	3.31	0.48	-71.56	-8.88	-91.25	-6.26	4
04	9-hydroxy-10,14-octadecadien-12-ynoic acid	8.54	-1.78	3.82	0.44	-143.64	-1.68	-241.54	-24.25	5
05	nicandrose E	8.52	-3.94	3.49	0.43	-80.82	-22.60	-125.52	-15.27	4
06	2-amino-1,3,4-tetradecanetriol	8.28	-1.74	2.91	0.33	-112.15	-9.15	-181.69	-16.81	4
07	linoleic acid	7.91	-4.05	1.25	0.29	15.56	-25.14	-117.63	-17.52	4
08	oleoyl ethanolamide	7.88	-1.46	2.18	0.39	-125.02	-12.83	-218.70	-19.90	4
09	sparalide A	7.51	-1.96	4.01	0.26	-87.78	-31.03	-227.42	-21.39	5



#	Compound name	Total score <sup>a</sup>	Crash	Polar	Similarity	D score	PMF score	G score	Chem score	C score
10	3-cyclohexene-1-butylaldehyde-3-hydroxy- $\alpha$ -isopropyl-1-methyl-2-oxo-disemicarbazone	6.42	-0.77	3.84	0.64	-191.24	-17.80	-331.39	-30.35	4
-	AZD0530 <sup>b</sup>	6.56	-1.91	1.61	0.53	-269.05	-9.08	-257.50	-23.27	5

**(d) Syk**



#	Compound name	Total score <sup>a</sup>	Crash	Polar	Similarity	D score	PMF score	G score	Chem score	C score
01	10-hydroxy-8,12-octadecadienoic acid	8.73	-1.52	2.64	0.50	-133.84	-7.64	-235.06	-23.09	4
02	rhizoleucinoside	8.49	-6.29	4.23	0.40	-125.91	-17.80	-223.20	-24.29	5
03	hurghamide D	8.45	-2.01	0.96	0.50	-135.88	-28.62	-217.54	-22.80	5
04	3-cyclohexene-1-butylaldehyde-3-hydroxy- $\alpha$ -isopropyl-1-methyl-2-oxo-disemicarbazone	8.19	-0.86	4.67	0.54	-215.83	-66.85	-357.98	-36.63	4
05	9-hydroxy-10,14-octadecadien-12-ynoic acid	7.91	-0.90	3.99	0.54	-101.02	-1.03	-161.06	-17.98	4
06	2-amino-1,3-hexadecanediol	7.13	-1.57	3.32	0.40	-111.23	-35.13	-238.07	-23.52	4
-	RO9021 <sup>b</sup>	6.32	-1.09	2.72	0.39	24559.12	-65.91	-213.14	-24.42	3

<sup>a</sup>) With the natural ligand of each protein as references, the RMSD was less than 2.0 for each match.

<sup>b</sup>) These compounds were known SFKs inhibitors, which were used as positive controls.





**Figure S1.** MS spectra and proposed fragment ions of riboflavin (**1**) in positive ion mode: (a) MS spectrum; (b) MS/MS spectrum (precursor ion was m/z 377).





**Figure S2.** MS spectra and proposed fragment ions of citric acid (**2**) in negative ion mode: (a) MS spectrum; (b) MS/MS spectrum (precursor ion was  $m/z$  191).









**Figure S3.** MS spectra and proposed fragment ions of ainsliatone A (**3**) in positive ion mode:  
 (a) MS spectrum; (b) MS/MS spectrum (precursor ion was m/z 251).




**Figure S4.** MS spectra and proposed fragment ions of ergosterol (**4**) in positive ion mode: (a) MS spectrum; (b) MS/MS spectrum (precursor ion was m/z 397).



**Figure S5.** MS spectra and proposed fragment ions of fraxinellone (**5**) in positive ion mode:  
 (a) MS spectrum; (b) MS/MS spectrum (precursor ion was m/z 233).




**Figure S6.** MS spectra and proposed fragment ions of mannitol (6) in positive ion mode: (a) MS spectrum; (b) MS/MS spectrum (precursor ion was  $m/z$  183)



**Figure S7.** Comparison of total ion current chromatograms (TIC) of *S. crispa* extracted with different solvents in positive (above) and negative (below) ion modes (The mobile phase was composed of 0.1% formic acid aqueous solution (A) and acetonitrile (B), and the gradient elution program was 5–100% B at 0–20 min)


## citricacidmonomethylester

S. crista Extracts\_Neg #530 RT: 1.38 AV: 1 NL: 7.81E7  
F: FTMS - c ESI d Full ms2 205.0351@hcd30.00 [50.0000-225.0000]




## methylsuccinicacid

S. crista Extracts\_Neg #618 RT: 1.61 AV: 1 NL: 1.10E6  
F: FTMS - c ESI d Full ms2 131.0362@hcd30.00 [50.0000-150.0000]




### 3-methylglutaricacid

S. crista Extracts\_Neg #914 RT: 2.38 AV: 1 NL: 1.75E6  
F: FTMS - c ESI d Full ms2 145.0519@hcd30.00 [50.0000-165.0000]




### 5'-deoxy-5'-methylthioadenosine

S. crista Extracts\_Pos #994 RT: 2.59 AV: 1 NL: 1.08E7  
F: FTMS + c ESI d Full ms2 298.0966@hcd30.00 [50.0000-320.0000]




## 2-amino-octanedioic acid

S. crispa Extracts\_Neg #1236 RT: 3.22 AV: 1 NL: 2.60E6  
F: FTMS - c ESI d Full ms2 188.0926@hcd30.00 [50.0000-210.0000]



## 4-hydroxy-5,7-dimethoxy-1-isobenzofuranone


S. crispa Extracts\_Pos #1616 RT: 4.21 AV: 1 NL: 1.24E7  
F: FTMS + c ESI d Full ms2 211.0602@hcd30.00 [50.0000-235.0000]






## glucitol

S. crispa Extracts\_Neg #2451 RT: 6.38 AV: 1 NL: 1.15E7  
F: FTMS - c ESI d Full ms2 181.0716@hcd30.00 [50.0000-200.0000]




## 2-amino-1,3-dodecanediol

S. crispa Extracts\_Pos #2608 RT: 6.79 AV: 1 NL: 3.31E7  
F: FTMS + c ESI d Full ms2 218.2115@hcd30.00 [50.0000-240.0000]




## stellarinC

S. crispa Extracts\_Pos #2621 RT: 6.83 AV: 1 NL: 4.99E5  
F: FTMS + c ESI d Full ms2 655.3087@hcd30.00 [50.0000-685.0000]




## 9-hydroxy-10,14-octadecadien-12-ynoic acid

S. crispa Extracts\_Pos #2993 RT: 7.79 AV: 1 NL: 1.05E5  
F: FTMS + c ESI d Full ms2 293.2111@hcd30.00 [50.0000-315.0000]




## clitocybulolC

S. crispa Extracts\_Neg #3197 RT: 8.32 AV: 1 NL: 7.28E5  
F: FTMS - c ESI d Full ms2 265.1480@hcd30.00 [50.0000-290.0000]




## 3 $\beta$ -hydroxy-11,12-O-isopropylidenedrimene

S. crispa Extracts\_Pos #3233 RT: 8.42 AV: 1 NL: 1.16E5  
F: FTMS + c ESI d Full ms2 295.2268@hcd30.00 [50.0000-320.0000]




### 9,12,13-trihydroxy-15-octadecenoic acid

S. crista Extracts\_Neg #3266 RT: 8.50 AV: 1 NL: 4.95E6  
F: FTMS - c ESI d Full ms2 329.2331@hcd30.00 [50.0000-355.0000]




### 5,8-dihydroxy-9,12-octadecadienoic acid

S. crista Extracts\_Neg #3704 RT: 9.64 AV: 1 NL: 2.92E6  
F: FTMS - c ESI d Full ms2 311.2225@hcd30.00 [50.0000-335.0000]




## porrigenicacid

S. crispa Extracts\_Neg #4000 RT: 10.41 AV: 1 NL: 3.19E5  
F: FTMS - c ESI d Full ms2 309.2067@hcd30.00 [50.0000-335.0000]




## 12-oxo-phytodienoicacid

S. crispa Extracts\_Pos #4096 RT: 10.66 AV: 1 NL: 1.79E5  
F: FTMS + c ESI d Full ms2 293.2111@hcd30.00 [50.0000-315.0000]




## nicandroseE

S. crista Extracts\_Neg #4792 RT: 12.47 AV: 1 NL: 3.23E6  
F: FTMS - c ESI d Full ms2 649.3436@hcd30.00 [50.0000-680.0000]




## 1,3-di(isobutoxycarbonyl)-2,4,4-trimethylpentane

S. crista Extracts\_Neg #4934 RT: 12.84 AV: 1 NL: 3.08E6  
F: FTMS - c ESI d Full ms2 313.2382@hcd30.00 [50.0000-335.0000]




### 10-hydroxy-8,12-octadecadienoic acid

S. crispa Extracts\_Neg #6246 RT: 16.26 AV: 1 NL: 3.10E5  
F: FTMS - c ESI d Full ms2 295.2275@hcd30.00 [50.0000-620.0000]




### 3-hydroxy-2-[[*(9Z)*-1-oxo-9-hexadecen-1-yl]oxy]propyl-β-D-galactopyranoside

S. crispa Extracts\_Neg #5378 RT: 14.00 AV: 1 NL: 6.45E6  
F: FTMS - c ESI d Full ms2 489.3066@hcd30.00 [50.0000-515.0000]




## 6,7-epoxystearic acid

S. crista Extracts\_Neg #5570 RT: 14.50 AV: 1 NL: 3.52E7  
F: FTMS - c ESI d Full ms2 297.2430@hcd30.00 [50.0000-320.0000]



## 1-(9-octadecenoate)- $\beta$ -D-glucopyranose


S. crista Extracts\_Pos #6615 RT: 17.22 AV: 1 NL: 2.24E4  
F: FTMS + c ESI d Full ms2 445.3161@hcd30.00 [50.0000-470.0000]






## 2,3-seco-2,3-dicarboxyplatanicacid

S. crispa Extracts\_Neg #5566 RT: 14.49 AV: 1 NL: 1.02E4  
F: FTMS - c ESI d Full ms2 503.3010@hcd30.00 [50.0000-530.0000]




## ganoderasideD

S. crispa Extracts\_Pos #5745 RT: 14.96 AV: 1 NL: 2.62E5  
F: FTMS + c ESI d Full ms2 409.3099@hcd30.00 [50.0000-435.0000]




## (5 $\alpha$ ,6 $\alpha$ )-epoxy-ergosta-8(14),22-diene-3 $\beta$ ,7 $\beta$ -diol

S. crispa Extracts\_Pos #6580 RT: 17.13 AV: 1 NL: 3.69E4  
F: FTMS + c ESI d Full ms2 429.3361@hcd30.00 [50.0000-455.0000]




## ergone

S. crispa Extracts\_Pos #7028 RT: 18.30 AV: 1 NL: 5.65E5  
F: FTMS + c ESI d Full ms2 393.3154@hcd30.00 [50.0000-420.0000]




## linoleic acid

S. crista Extracts\_Neg #6758 RT: 17.59 AV: 1 NL: 1.39E7  
F: FTMS - c ESI d Full ms2 279.2326@hcd30.00 [50.0000-305.0000]




## oleamide

S. crista Extracts\_Pos #6862 RT: 17.86 AV: 1 NL: 2.28E5  
F: FTMS + c ESI d Full ms2 282.2790@hcd30.00 [50.0000-305.0000]




## ergosterolperoxide

S. crispa Extracts\_Pos #7436 RT: 19.36 AV: 1 NL: 7.17E4  
F: FTMS + c ESI d Full ms2 429.3361@hcd30.00 [50.0000-455.0000]




## ergosta-5,8,22-triene-3,11-dione

S. crispa Extracts\_Pos #6394 RT: 16.65 AV: 1 NL: 3.44E5  
F: FTMS + c ESI d Full ms2 409.3099@hcd30.00 [50.0000-435.0000]




## thraustochytrosideA

S. crispa Extracts\_Pos #8265 RT: 21.52 AV: 1 NL: 8.19E6  
F: FTMS + c ESI d Full ms2 710.5563@hcd30.00 [50.0000-740.0000]



## erucamide


S. crispa Extracts\_Pos #8408 RT: 21.89 AV: 1 NL: 1.23E6  
F: FTMS + c ESI d Full ms2 338.3415@hcd30.00 [50.0000-365.0000]



# 1-(hydroxymethyl)-2-[(1-oxohexadecyl)oxy]ethyl-ester-9,12-heptadecadienoic acid

S. crispa Extracts\_Neg #8612 RT: 22.43 AV: 1 NL: 3.18E6

F: FTMS - c ESI d Full ms2 577.4834@hcd30.00 [50.0000-605.0000]



**Figure S8.** Chemical structures and available raw MS<sup>2</sup> spectra of some components identified from *S. crispa*